Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) is projected to announce its resultson Monday, August 10th. Analysts expect the company to post earnings of ($56.25) per share for the quarter.
Avenue Therapeutics Price Performance
Shares of Avenue Therapeutics stock opened at $0.39 on Monday. The firm has a market capitalization of $1.28 million, a PE ratio of 0.02 and a beta of -0.17. The company’s fifty day moving average price is $0.31 and its two-hundred day moving average price is $0.33. Avenue Therapeutics has a 52-week low of $0.15 and a 52-week high of $0.97.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Read More
- Five stocks we like better than Avenue Therapeutics
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
